RxDoctor Payments DataLook up a doctor →

Huiming Hon, MD

Gastroenterology · Atlanta, GANPI 1780854109

Payments from drug & device makers

$159,077in general payments, 2019–2025

Across 604 payments — averaging $263.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$49K
  • Intercept Pharmaceuticals, Inc.$44K
  • Ipsen Biopharmaceuticals, Inc$34K
  • Gilead$19K
  • AbbVie$6K
  • Boehringer Ingelheim$3K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$13,9889%
  • Speaking & faculty fees$118,15874%
  • Travel & lodging$11,8457%
  • Food & beverage$14,9599%
  • Education$1270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$159,077 in reported general payments places this provider in the 90th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$213,454
Medicare patients
528
Services billed
4,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin42$239,691
VemlidyTenofovir Alafenamide76$133,180
RezdiffraResmetirom11$53,301
Ursodiol162$38,284
CreonLipase/Protease/Amylase11$27,550
Dexlansoprazole DrDexlansoprazole24$7,319
Entecavir20$5,067
Sucralfate31$4,952
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates58$3,929
Pantoprazole Sodium195$3,041
Lactulose72$2,200
ConstuloseLactulose11$1,661
Nadolol30$1,355
Famotidine88$1,325
Bumetanide24$1,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,191$239,69142 claims
GileadVemlidy$19,076$133,18076 claims
Madrigal PharmaceuticalsRezdiffra$48,644$53,30111 claims
AbbVieCreon$6,298$27,55011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →